Using Machine Learning to Create Prognostic Systems for Primary Prostate Cancer
Kevin Guan1,2, Andy Guan1,3, Anwar E Ahmed1
1F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD 20814, USA.
None:
Background: Cancer staging, guided by anatomical and clinicopathologic factors, is essential for determining treatment strategies and patient prognosis. The current gold standard for prostate cancer is the American Joint Committee on Cancer (AJCC) Tumor, Lymph Node, and Metastasis (TNM) Staging System 9th Version (2024). This system incorporates five prognostic variables: tumor (T), spread to lymph nodes (N), metastasis (M), prostate-specific antigen (PSA) levels (P), and Grade Group/Gleason score (G). While effective, further refinement of prognostic systems may improve prediction of patient outcomes and support more individualized treatment. Methods: We applied the Ensemble Algorithm for Clustering Cancer Data (EACCD), an unsupervised machine learning approach. EACCD involves three steps: calculating initial dissimilarities, performing ensemble learning, and conducting hierarchical clustering. We first developed an EACCD model using the five AJCC variables (T, N, M, P, G). The model was then expanded to include two additional factors, age (A) and race (R). Prostate cancer patient data were obtained from the Surveillance, Epidemiology, and End Results (SEER) program from the National Cancer Institute. Results: The EACCD algorithm effectively stratified patients into distinct prognostic groups, each with well-separated survival curves. The five-variable model achieved a concordance index (C-index) of 0.8293 (95% CI: 0.8245-0.8341), while the seven-variable model, including age and race, improved performance to 0.8504 (95% CI: 0.8461-0.8547). Both outperformed the AJCC TNM system, which had a C-index of 0.7676 (95% CI: 0.7622-0.7731). Conclusions: EACCD provides a refined prognostic framework for primary localized prostate cancer, demonstrating superior accuracy over the AJCC staging system. With further validation in independent cohorts, EACCD could enhance risk stratification and support precision oncology.
More Related Videos
08:05Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
